Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report released on Thursday. The brokerage set a “buy” rating on the biotechnology company’s stock.

ADAP has been the topic of a number of other reports. HC Wainwright decreased their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Guggenheim decreased their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Mizuho decreased their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $2.79.

Adaptimmune Therapeutics Stock Performance

Shares of NASDAQ ADAP opened at $0.45 on Thursday. The stock has a market cap of $115.22 million, a price-to-earnings ratio of -2.05 and a beta of 2.52. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 1-year low of $0.44 and a 1-year high of $1.65. The stock’s 50-day moving average is $0.57 and its 200 day moving average is $0.73.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP grew its position in Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 19,146 shares during the last quarter. Virtu Financial LLC lifted its stake in Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 21,688 shares during the period. Invesco Ltd. lifted its stake in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 28,526 shares during the period. FMR LLC boosted its holdings in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after acquiring an additional 50,419 shares in the last quarter. Finally, Rock Springs Capital Management LP increased its position in Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 58,000 shares during the period. 31.37% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.